Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, succeeding Alan Holmer who will remain on the Board. Jacques, who has served on Corbus' Board for over six years, brings more than 25 years of leadership experience across CEO, commercial, financial, and operational roles. The appointment comes at a crucial time as Corbus anticipates clinical readouts from all three drugs in its pipeline in the second half of 2025, including targeted oncology programs CRB-701 and CRB-601, and an obesity program.
Jacques' extensive experience includes serving as CEO of Akari Therapeutics and Enzyvant Therapeutics, where she achieved FDA approval for RETHYMIC®. She has also held executive positions at Alexion Pharmaceuticals, Baxalta, and Baxter International. Currently, she serves on the board of directors of uniQure N.V. and holds a bachelor's degree in business administration from Alma College.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha nominato Rachelle Jacques come Presidente del Consiglio di Amministrazione, con effetto dal 15 maggio, succedendo ad Alan Holmer che rimarrà nel Consiglio. Jacques, che fa parte del Consiglio di Corbus da oltre sei anni, vanta più di 25 anni di esperienza dirigenziale in ruoli da CEO, commerciali, finanziari e operativi. La nomina arriva in un momento cruciale, poiché Corbus prevede i risultati clinici di tutti e tre i farmaci in pipeline nella seconda metà del 2025, inclusi i programmi oncologici mirati CRB-701 e CRB-601, oltre a un programma per l'obesità.
L'ampia esperienza di Jacques comprende il ruolo di CEO presso Akari Therapeutics e Enzyvant Therapeutics, dove ha ottenuto l'approvazione FDA per RETHYMIC®. Ha inoltre ricoperto posizioni dirigenziali in Alexion Pharmaceuticals, Baxalta e Baxter International. Attualmente, è membro del consiglio di amministrazione di uniQure N.V. e possiede una laurea in amministrazione aziendale presso Alma College.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha nombrado a Rachelle Jacques como Presidenta de su Junta Directiva, con efecto a partir del 15 de mayo, sucediendo a Alan Holmer, quien permanecerá en la Junta. Jacques, que ha formado parte de la Junta de Corbus durante más de seis años, aporta más de 25 años de experiencia en liderazgo en roles de CEO, comerciales, financieros y operativos. El nombramiento llega en un momento crucial, ya que Corbus anticipa los resultados clínicos de los tres medicamentos en su cartera en la segunda mitad de 2025, incluyendo los programas oncológicos dirigidos CRB-701 y CRB-601, y un programa para la obesidad.
La amplia experiencia de Jacques incluye haber sido CEO de Akari Therapeutics y Enzyvant Therapeutics, donde logró la aprobación de la FDA para RETHYMIC®. También ha ocupado cargos ejecutivos en Alexion Pharmaceuticals, Baxalta y Baxter International. Actualmente, forma parte del consejo de administración de uniQure N.V. y tiene una licenciatura en administración de empresas por Alma College.
Corbus Pharmaceuticals (NASDAQ: CRBP)는 5월 15일부로 이사회 의장에 Rachelle Jacques를 임명했으며, Alan Holmer는 이사회에 계속 남아 있습니다. Jacques는 6년 넘게 Corbus 이사회에서 활동해 왔으며, CEO, 상업, 재무 및 운영 분야에서 25년 이상의 리더십 경험을 보유하고 있습니다. 이번 임명은 Corbus가 2025년 하반기에 파이프라인 내 세 가지 약물 모두의 임상 결과 발표를 앞두고 있는 중요한 시기에 이루어졌으며, 여기에는 표적 항암 프로그램 CRB-701 및 CRB-601과 비만 프로그램이 포함됩니다.
Jacques는 Akari Therapeutics와 Enzyvant Therapeutics의 CEO로 재직하며 RETHYMIC®의 FDA 승인을 이끌어낸 경력이 있습니다. 또한 Alexion Pharmaceuticals, Baxalta, Baxter International에서 임원직을 역임했습니다. 현재 uniQure N.V.의 이사회 멤버이며 Alma College에서 경영학 학사 학위를 받았습니다.
Corbus Pharmaceuticals (NASDAQ : CRBP) a nommé Rachelle Jacques présidente de son conseil d'administration, à compter du 15 mai, succédant à Alan Holmer qui restera membre du conseil. Jacques, qui siège au conseil de Corbus depuis plus de six ans, possède plus de 25 ans d'expérience en leadership dans des rôles de PDG, commerciaux, financiers et opérationnels. Cette nomination intervient à un moment crucial, alors que Corbus anticipe les résultats cliniques de ses trois médicaments en développement au second semestre 2025, incluant les programmes oncologiques ciblés CRB-701 et CRB-601, ainsi qu'un programme contre l'obésité.
L'expérience approfondie de Jacques inclut son rôle de PDG chez Akari Therapeutics et Enzyvant Therapeutics, où elle a obtenu l'approbation de la FDA pour RETHYMIC®. Elle a également occupé des postes de direction chez Alexion Pharmaceuticals, Baxalta et Baxter International. Elle siège actuellement au conseil d'administration de uniQure N.V. et est titulaire d'une licence en administration des affaires de l'Alma College.
Corbus Pharmaceuticals (NASDAQ: CRBP) hat Rachelle Jacques zum Vorsitz der Geschäftsleitung ernannt, mit Wirkung zum 15. Mai, als Nachfolgerin von Alan Holmer, der im Vorstand verbleibt. Jacques, die seit über sechs Jahren im Vorstand von Corbus tätig ist, bringt mehr als 25 Jahre Führungserfahrung in den Bereichen CEO, Vertrieb, Finanzen und Betrieb mit. Die Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Corbus für die zweite Hälfte des Jahres 2025 klinische Ergebnisse aller drei Medikamente in der Pipeline erwartet, darunter die zielgerichteten Onkologieprogramme CRB-701 und CRB-601 sowie ein Adipositas-Programm.
Jacques' umfassende Erfahrung umfasst die Tätigkeit als CEO von Akari Therapeutics und Enzyvant Therapeutics, wo sie die FDA-Zulassung für RETHYMIC® erreichte. Sie hatte außerdem Führungspositionen bei Alexion Pharmaceuticals, Baxalta und Baxter International inne. Derzeit ist sie Mitglied des Vorstands von uniQure N.V. und hat einen Bachelor-Abschluss in Betriebswirtschaft von Alma College.
- Appointment of an experienced leader with 25+ years of leadership across CEO, commercial, financial, and operational roles
- Multiple clinical readouts expected in H2 2025 from three pipeline drugs
- New chair brings successful track record in FDA approvals and commercialization strategy
- None.
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board.
“We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we enter an exciting new chapter for Corbus, with clinical readouts from all three of the drugs in our pipeline expected in the 2nd half of this year”.
"It is a privilege to step into the Board Chair role at such a pivotal time for Corbus as we advance our diverse pipeline toward key milestones this year,” said Rachelle Jacques. “Our targeted oncology programs, CRB-701 and CRB-601, are designed to strike at the heart of aggressive cancers, while our obesity program has the potential to address one of the most urgent public health challenges of our time. The opportunity to drive meaningful change for patients is immense and deeply motivating."
“It has been an honor and privilege to serve as Chair of the Corbus Board”, said Alan Holmer. “We are clearly on a positive and exciting trajectory. Rachelle has been a highly valued member of the Board and brings deep and broad corporate experience in both big pharma and biotech. I look forward to working closely with her to ensure a smooth transition.”
Rachelle Jacques has served on the Corbus Pharmaceuticals Board of Directors for more than six years, contributing to the Audit, Compensation, and Governance and Nominating Committees. With more than 25 years of leadership experience across CEO, commercial, financial, and operational roles, she has a strong track record of success advancing and launching transformative therapies. Jacques also serves on the board of directors of uniQure N.V. (Nasdaq: QURE), a biotechnology company advancing gene therapies for patients with severe genetic diseases. She was previously CEO and a board member of Akari Therapeutics Plc (Nasdaq: AKTX), a late-stage biotechnology company developing treatments for autoimmune and inflammatory diseases. Before that, she served as CEO of Enzyvant Therapeutics, where she led the successful U.S. Food and Drug Administration approval of RETHYMIC®, one of the first three therapies authorized under the Regenerative Medicine Advanced Therapy (RMAT) designation.
Earlier in her career, Jacques held executive roles including senior vice president and global complement franchise head at Alexion Pharmaceuticals, where she led global commercialization strategy across hematology, nephrology, and neurology. She also served as vice president of U.S. hematology marketing at Baxalta, vice president of business operations at Baxalta following its spinoff from Baxter International, and held multiple leadership positions at Baxter, including vice president of finance for the U.S. BioScience business. At Dow Corning she held operational management roles across the United States, Europe, and China. Jacques earned a bachelor’s degree in business administration from Alma College, where she also serves on the board of trustees.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
Who is the new Board Chair of Corbus Pharmaceuticals (CRBP)?
What is Rachelle Jacques' experience in the pharmaceutical industry?
What are the upcoming milestones for Corbus Pharmaceuticals (CRBP) in 2025?
What is Corbus Pharmaceuticals' (CRBP) current focus area?
